Announcements Trials
Browse Landscape

Phase

Phase 2 165Phase 1/2 73Phase 1 59Phase 3 42Phase NA 4Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 10Lymphoid 2

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Cyclophosphamide 27Vincristine 24Dexamethasone 22Rituximab 21Methotrexate 21Cytarabine 21Mercaptopurine 16Doxorubicin 15Etoposide 13Asparaginase 13Daunorubicin 12Prednisone 10Prednisolone 10Granulocyte Colony-Stimulating Factor 10Ifosfamide 8Idarubicin 8fludarabine 7pegylated granulocyte colony-stimulating factor 6Thioguanine 6Teniposide 6Vindesine 5Brentuximab Vedotin 5ibrutinib 4fludarabine phosphate 4Stem Cell Transplantation 4Gemcitabine 4Cisplatin 4Aprepitant 4zanubrutinib 3prednylidene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Lenalidomide × Lymphoid × Clear all
NCT04040491 2020-05-12

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Zhengzhou University

Phase 4 Unknown
100 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04038411 2019-07-30

PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

Zhengzhou University

Phase 4 Unknown
50 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡